

Company Registered Number: 02685083
Charity Registered Number (England & Wales): 1009671

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

CONTENTS

	Page
Reference and Administrative Details of the Charity, its Trustees and Advisers	1
Trustees' Report	2 - 11
Trustees' Responsibilities Statement	12
Independent Examiner's Report	13 - 14
Consolidated Statement of Financial Activities	15
Consolidated Balance Sheet	16 - 17
Charity Balance Sheet	18 - 19
Consolidated Statement of Cash Flows	20
Notes to the Financial Statements	21 - 45

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 DECEMBER 2024

Trustees	Stephen Pugh, Chair Hannah Kunzlik Professor Celia Moss OBE James Pitayanukul, Treasurer Hedwig Vollers Suzanne Watson
Company registered number	02685083
Charity registered number	1009671
Registered office	82 Tanner Street London SE1 3GN United Kingdom
Chief executive officer & Company secretary	Andrew Proctor
Independent Examiner	MHA Chartered Accountants MHA House Charter Court Swansea Enterprise Park Swansea SA7 9FS
Principal Bankers	CAF Bank Ltd National Westminster Bank plc
Status and Governing Document	National Eczema Society is a charitable company, limited by guarantee. It was incorporated on 6 February 1992 and registered as a charity on 10 March 1992. It is governed by its Articles of Association.
Subsidiary Companies	Eczema Trading Limited

NATIONAL ECZEMA SOCIETY**(A Company Limited by Guarantee)**

**TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024**

The trustees present their annual report together with the financial statements of the Group and the Charity for the year 1 January 2024 to 31 December 2024. The trustees confirm that the Annual Report and financial statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). Since the Charity and the Group qualifies as small under section 383, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director's Report) Regulations 2013 is not required.

Purpose and Aims

National Eczema Society was established in 1975 to support people with eczema and their families and to work on their behalf. The charity is celebrating its 50th anniversary in 2025. We remain dedicated to these founding principles and today we continue to help people across the UK by providing evidence-based information and advice about eczema and its management. We deliver this in various ways through our website, webinars, instructional videos, social media communications and publications. We also provide a collective voice for people with eczema, fund and inform research, influence health policy to improve eczema care, and raise greater awareness and understanding of the condition among people affected by eczema and the wider public.

The prevalence of eczema has increased over recent decades, and around one in five children and one in ten adults are now impacted by this life-limiting condition in the UK. While the reasons for the increase are not fully understood, it does mean the charity's work is needed more than ever. There is no cure for eczema and, unless you have the condition, it can be hard to understand the daily challenge of living with relentless itching and inflamed, painful skin. Many healthcare professionals have limited dermatology training and timely access to specialist dermatology healthcare for people with eczema can often be difficult. National Eczema Society aims to provide the information and support needed for people to self-manage their eczema effectively, to become experts in their own care, learn from the experiences of others, and provide the reassurance of knowing they are not on their own.

Ensuring Our Work Delivers Our Charitable Aims

We review our activities each year and monitor the impact of our work to ensure we continue to fulfil our purpose of supporting people affected by eczema. Among other ways, we assess the Society's performance and achievements through the number of people we have helped with information and advice, the quality and consistency of the resources we provide, the eczema research we support, and the policy influencing we achieve.

We consider how planned activities will contribute to the aims and objectives we have set, and in doing this we have referred to the Charity Commission's general guidance on public benefit. We have had regard to the legislative and regulatory requirements for disclosing how our charitable objectives have provided such benefit, and complied with the duty set out in section 4 of the Charities Act 2011.

2024 Activity and Achievements - Delivering Public Benefit

All our charitable activities focus on supporting people affected by eczema and championing their needs, and further our charitable purposes for the public benefit. Here we present a summary of the Society's work over the year.

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

Strategic Review and Implementation

During the year we implemented a strategic review, with the purpose of enabling the charity to better serve the UK eczema community. We are a relatively small charity, serving a very large community of people affected by eczema – over eight million adults and children in the UK and their families. With limited funding, it is important the charity prioritises its resources to achieve the biggest impact we can for people with eczema. Our strategy is now focusing more on our work supporting eczema research, to develop better treatments and ultimately a cure, and influencing for better eczema care for all sufferers. These enable us to become a stronger collective voice for the eczema community, as we recognise too many people are struggling to achieve a good quality of life because of their eczema and need better care.

The change of focus brought about through the strategic review required some challenging choices, including withdrawing from providing personalised advice on managing eczema. This included taking the difficult decision to close the Society's eczema helpline service, in March 2024. We recognise this was disappointing for supporters and others who have used the Society's helpline in the past and have appreciated the advice we provided. We are committed to expanding other information resources, which are used by many people in our community. We were able to support around 1,000 callers a year to the helpline.

The strategic review proposed a number of new staff roles, and we recruited three new members of staff during the year, to lead on the Society's health content, research engagement, and communications and campaigning work. Under the new strategy, several existing staff roles were no longer required, and it is with regret these posts were made redundant in March 2024.

The Society's three core areas of charitable work continue to be:

- Providing eczema information and advice
- Supporting eczema research
- Advocacy and improving eczema care.

Providing Information and Advice for People Living with Eczema

The Society continues to provide a wide range of high quality, evidence-based information about eczema and its management for the UK eczema community. We produce a range of patient information booklets and factsheets about eczema management and treatment, available online and in print. We distribute printed copies at the events we organise and attend, and we provided over 17,500 copies of our printed publications to healthcare professionals during the year, for onward distribution to patients in hospital dermatology clinics and other healthcare settings across the UK. Our most popular booklets are Childhood Atopic Eczema and Itching and Scratching.

National Eczema Society factsheets and booklets are updated regularly on a rolling review cycle and checked by healthcare professionals to ensure the information is accurate and up-to-date. We updated and reprinted a number of publications over the year, including our Guide for Teenagers with Eczema and Eczema Guide for Healthcare Professionals.

Our eczema information is available on the Society's website, which received over two million visits during the year. Our webpages on facial eczema, seborrhoeic dermatitis, emollients, eye and ear eczema, hand eczema, topical steroid treatments, topical steroid withdrawal, pompholyx eczema and scalp eczema remain especially popular. Additionally, over 35,000 copies of our factsheets were downloaded during the year. We also promote health advice messages through our social media posts, e-newsletters, media engagement and other external communications.

In August, we launched a regular monthly email newsletter for supporters who have signed-up via our website to receive email communications from National Eczema Society. Over 10,000 people affected by

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

eczema now benefit from regular email updates on eczema news and developments, and about the work of the charity. We have received positive audience feedback on our e-newsletters and the mailing list continues to grow.

We launched the Exploring Eczema webinar series in September, presented by Dermatology Nurse Advisor Julie Van Onselen. We are planning eight webinars on different topics during 2024/2025 including, emollients, eczema triggers and managing baby and toddler eczema. Typically, between 100 and 200 people attend each of our webinars, with many more viewing the webinar recordings on our YouTube channel. We also continued our popular programme of webinars with St John's DermAcademy (part of Guy's and St Thomas' Hospital, London) to jointly deliver two events, one focusing on managing eczema itch and the other on facial eczema. Recordings of several past webinars are also available to view on the Society's social media pages or YouTube channel.

As noted above, the Society took the decision to close its eczema helpline service in March 2024, as part of a wider strategy change to focus more resources on supporting eczema research, campaigning for better eczema care, and broadening our information offer with new resources like webinars.

We continue to raise awareness of local volunteer-led patient support groups, by providing information and a presence for these groups on the Society's website. The West Surrey and North-East Hampshire Support Group held a number of fundraising events over the year and organised an information day in Guildford in February on the 'Combined Approach' to managing eczema. Dr Alpa Kanji talked about how habit reversal therapy combined with topical treatments can help people with eczema break the habitual eczema itch-scratch cycle. Dr Kanji is a dermatologist working at St John's Institute of Dermatology in London and she teaches habit reversal therapy. The event was livestreamed and recorded on Facebook, enabling many more people with eczema to access the talk.

NES Membership Scheme

National Eczema Society is a membership organisation and we are very grateful to our 2,000 members who support the Society through their annual membership fee and additional donations. Members receive our membership magazine Exchange, which features expert information and news about eczema. Members are also encouraged to attend the Society's Annual General Meeting and contribute their ideas on the running of the charity. As in previous years, support for our charity extends far beyond our membership and we remain grateful to all our donors, and to those members who continue to support us financially even though they no longer have any personal need of our help.

Income from the membership scheme has fallen as the number of members has gradually declined over the years. We took the difficult decision to move to producing two issues annually of Exchange magazine starting in 2024, replacing the previous quarterly publishing schedule, so that membership scheme costs are better aligned with membership income.

Supporting Eczema Research

National Eczema Society launched its first-ever eczema research call in December 2024, inviting research teams in UK universities to apply for funding from the charity. We want to improve the understanding and treatment of eczema and topical steroid withdrawal (TSW) and more research will help achieve this goal. The Society invited applications for innovation grants to fund new research ideas, as well as pump-priming grants to fund early-stage studies, enabling researchers to collect proof-of-concept data needed to take the research forward in larger studies. We also invited applications for PhD studentships, to support the next generation of world-leading eczema researchers. The applications were assessed in Spring 2025, and the awards announced early summer 2025. It is our intention to hold an eczema research call annually, subject to sufficient charity funds being available.

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

Building our internal research administration capability, the Society applied for and joined the Association of Medical Research Charities (AMRC) and has already benefitted from the AMRC's information and policy resources and training. This UK-based group represents and supports over 150 charities that fund medical research. National Eczema Society has also joined the Charities Research Involvement Group (CRIG), enhancing our ability to connect with patients, caregivers, other medical charities and healthcare professionals who share our passion for improving the lives of those affected by eczema.

During the year we established an 'Experts by Experience' (EXEC) patient group, to ensure the experiences and views of people living with eczema are fully considered in the Society's work. The 25-strong group includes both adults living with eczema and parents of children living with the condition. EXEC members provide feedback on eczema research initiatives, including projects funded by the Society, and a patient perspective on the charity's wider activities.

We continue to support patient involvement in shaping research. NES is approached regularly by researchers seeking patient views and to learn from patient experiences. It is so encouraging to see such a range of research underway and new treatments in the pipeline, following a long period when eczema was largely overlooked. The Society actively supports eczema research by participating in study steering groups, providing patient perspectives for research projects, promoting surveys, supporting patient recruitment for trials, and working with universities and companies that are assessing and developing new drug treatments. We do this to help ensure eczema research has the greatest chance of success in finding new treatments and ultimately a cure. Projects supported during the year include:

- A-STAR – UK-Irish Atopic Eczema Systemic Therapy Register
- BEACON Trial – Best systemic treatments for adults with atopic eczema over the long term
BEACONomics – study embedded within the BEACON Trial
- BIOMAP Innovative Medicines Initiative – Biomarkers in Atopic Dermatitis and Psoriasis
- END-ITCH Study – Eczema and Dermatitis, Implementing the Combined Approach
- Kids in Control Study – scratching awareness and behaviour change in children
- LEAD Study – pre-natal, pregnancy and post-natal eczema care and concerns of women of child bearing age
- Navigating Primary Care with Topical Steroid Withdrawal Study
- RAPID – Eczema Trials Programme
- SOCX Survey – looking at how skin colour affects the experience of people with eczema, acne and psoriasis
- SLEEP Study – Supporting children's sleep in those with eczema programme
- SMEDISS Study – exploring social media conversations about Janus-Kinase (JAK) Inhibitor medicines
- TLA4AE Study – temperature controlled laminar air flow device study
- TRANS-FOODS Study – aiming to prevent peanut allergy.

National Eczema Society provides a patient perspective for clinical guideline development, the assessment of new eczema treatments, and policy consultations. During the year, we continued to contribute patient insights and evidence for the assessment by the National Institute of Health and Care Excellence (NICE) of a new monoclonal antibody drug called lebrikizumab, used to treat moderate-to-severe eczema. This was approved by NICE in June 2024 and is the third biologic treatment for eczema after dupilumab and tralokinumab. As eczema affects people in different ways, it is very important we have a range of NHS treatment options to help ensure people can access a medicine that works effectively for them. We also provided patient evidence for the assessment by NICE of a new JAK Inhibitor topical treatment called delgocitinib for chronic hand eczema. The decision by NICE on whether delgocitinib will be approved for use by the NHS in England and Wales is expected mid-2025.

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

Advocacy and Improving Eczema Care

The charity undertakes a range of activities to raise awareness and understanding of eczema among the general public, influence for improved care, and to promote the information and advice the Society provides for people living with eczema and their families.

National Eczema Society scored a big win for the UK eczema community during the year. We were delighted when the MHRA, the UK medicines regulator, announced it was going to introduce clear strength labelling of topical steroids (TCS). This was in response to the Society's campaign launched a year earlier, calling on the MHRA to mandate clear strength labelling on topical steroid tubes, packaging and patient information leaflets. Prior to this, steroid creams and ointments used in the UK did not clearly show their strength on the tube or box.

Topical steroids are used by millions of adults and children in the UK to treat or prevent eczema flare-ups. It is important patients and their carers have the right information to use these medicines safely and effectively to manage eczema well. Topical steroids are effective treatments for eczema but, like many treatments, they can have side effects. People with eczema and carers are understandably concerned about overusing TCS. We believe clear potency labelling will help improve patient understanding and confidence in these widely-used medicines.

Our campaign had strong support from the eczema community. Some 95% of respondents in our online patient survey said they wanted to see clear strength labelling on all steroid creams and ointments. In a second patient survey we conducted, 98% of respondents knew steroid creams and ointments came in different strengths (potencies). However, almost half said they didn't know how many different strengths there were, and only 17% correctly answered '4'. Worryingly, 1 in 5 respondents in the survey underestimated the strength of their topical steroid and almost a quarter overestimated this. We recommended the MHRA use the words 'mild steroid', 'moderate steroid', 'strong steroid' or 'very strong steroid' on the labels, and we are delighted this has been adopted.

The MHRA announced the change in May 2024 and gave manufacturers 12 months to implement the new strength labelling, which is to appear on the packaging, tube and patient information leaflet for all topical steroid products. We are grateful to the eczema community for getting behind this initiative and to the professional dermatology bodies and other charities for supporting the campaign. We believe this is a significant step forward in supporting people to use these widely prescribed medicines safely and effectively.

Representing Patient Views

As a national patient organisation for the UK eczema community, the Society provides a collective voice to champion the needs of those affected by the condition. We seek to improve health outcomes for people with eczema by influencing health policy and participating in groups like the Dermatology Council for England and working with professional bodies like the British Association of Dermatologists (BAD), British Dermatological Nursing Group (BDNG), and Primary Care Dermatology Society (PCDS).

Patient interest and awareness of the side effects of topical steroid medication remains high, including concerns about topical steroid withdrawal (TSW), which feature widely on social media. Our website information on TSW is especially popular, attracting over 100,000 page views a year. TSW is complex and symptoms can be extremely painful and distressing. We are calling for more research into the causes, symptoms and treatments of TSW.

National Eczema Society worked with the British Association of Dermatologists and British Dermatological Nursing Group, to update our Joint Statement on TSW, first published 2021. We believe it is important for professional dermatological organisations and patient groups to work together to find better ways of diagnosing and supporting people with TSW. The updated Joint statement was published in February 2024. This builds on the earlier version, setting out what we know about TSW from the latest medical information available.

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

The British Association of Dermatologists has formed a Topical Steroid Withdrawal Working Party Group, in collaboration with National Eczema Society and other organisations, with the aim of producing expert consensus guidance on to support people with concerns about TSW. This includes producing a Patient Information Leaflet and any revisions to the TSW Joint Statement. The work is ongoing.

The UK medicines regulator, the MHRA updated its guidance on topical steroid safety during the year and National Eczema Society was pleased to contribute to this review.

National Eczema Society is working with corporate partner Aspire Pharma on a joint campaign to raise awareness and highlight the impact of menopause on eczema. There is limited research on the impact on women's skin during menopause. To learn more, we asked women living in the UK who are perimenopausal, menopausal or have been through the menopause to share their experiences in an online survey. We plan to announce the survey results next year.

During National Eczema Week in September, we highlighted the impact of eczema on people's mental health and emotional well-being, under the theme #LetsStartTheConversation. Our campaign encouraged open dialogue about eczema with friends, family, colleagues and healthcare professionals, and we created conversational resources to help our community to break the silence and open up about how eczema makes you feel. People often face particular challenges managing eczema at work, and we promoted our information resources to support with this. Many thanks to everyone in our community who shared their stories with us, raising awareness about living with eczema and how it affects mental health.

Media and Social Media Engagement

The Society provided information for a number of eczema stories in the media over the year. This included media comment for stories about eczema treatments on BBC Breakfast, synthetic skin research by Reuters, miracle eczema cures in The Telegraph, psychodermatology in the Sunday Times, and the new treatment for moderate-to-severe eczema called lebrikizumab in a range of media outlets. We contributed to a powerful story by the BBC in November about the huge impact eczema can have on people's lives, which featured the experiences of Chloe North, who has also been featured in the Society's Exchange magazine. The charity was featured in several professional publications including Pharmaceutical Journal, covering the MHRA announcement about new strength labelling for topical steroids. The Society was approached several times for media comment about topical steroid withdrawal (TSW) and we were mentioned in a feature on this by ITV This Morning, and in a BBC online story about TSW that included comment by National Eczema Society Trustee Professor Celia Moss.

We continued to expand our social media reach and activity during the year, reflecting how people increasingly seek and share information about eczema. The Society continues to grow its followers on Facebook, Instagram, X/Twitter and LinkedIn, with a combined social media following of over 45,000.

Growing Income and Building Financial Sustainability

We continue to commit resources to income generation, to achieve our charitable objectives and build future financial sustainability.

We would like to thank the many people who, as in previous years, by joining or renewing their membership, supporting our appeals and fundraising in a variety of often innovative ways, have enabled us to continue our work. The efforts and contribution of supporters and volunteers is invaluable to the Society. In particular, we are immensely grateful to our thoughtful and generous supporters who choose to leave a gift to National Eczema Society in their Will. We are grateful also to the charitable trusts and companies that have supported us during the year, and to all the healthcare professionals who have provided us with so much time, advice and support especially members of the Medical Advisory Board.

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

We continue to develop partnerships with companies that share our values and are willing to support our work and engage in joint education and awareness-raising activity. During the year we worked with AbbVie, Ammirall, Aspire Pharma, Bioderma, Dermal Laboratories, Lilly, LEO Pharma and Sanofi.

There were many fundraising highlights during the year. Income from challenge events, including the London Marathon and Great North Run, was strong again in 2024 and we thank all our supporters for raising funds and awareness of eczema by participating in events like these. The Great South Run 2024 was cancelled at late notice due to bad weather, and we appreciated the support of our runners in this event and the funds they raised for the charity despite the disappointment of the event cancellation.

The Society's West Surrey and North-East Hampshire Support Group undertook various local fundraising activities around Guildford and presented a cheque for £2,000 at the Society's Annual General Meeting in September. Our members and donors generously supported our summer and Christmas fundraising appeals once again and we are grateful to everyone who supported the Society in different ways with their donations.

Organisational Development

During the year, we implemented our plans for the Society's office move. The lease on the charity's current offices at 11 Murray Street, London NW1 9RE expires in March 2025. We started our phased move into shared workspace offices at 82 Tanner Street, London, SE1 3GN, United Kingdom in December, to be completed by end February 2025.

2025 Plans and Development Priorities

Looking ahead, we aim to ensure National Eczema Society continues to achieve the greatest impact we can for the UK eczema community including our members. The charity's core work will continue, as we expand our support for eczema research and advocacy work in line with our strategy. We are celebrating the Society's 50 anniversary in 2025 and will be highlighting this milestone in our charity magazine Exchange and in other communications. During the year we will also continue scoping work to refresh the charity's brand and visual identity.

Priorities for 2025 include:

Providing Information and Advice

- Continue providing high-quality information and advice about eczema, disseminated through the Society's website, printed publications, Exchange magazine, e-newsletters, and webinars including the popular new Exploring Eczema webinar series.
- Scope Patient Information Forum 'Tick' quality accreditation.
- Grow our social media activity and followings, including LinkedIn and YouTube channel.

Supporting Eczema Research

- Deliver the planned eczema and TSW research call, establishing an expert panel to assess grant applications and recommend research awards.
- Grow our EXEC patient panel of people who are willing to share their experiences of living with eczema with researchers.
- Scope and provide leadership for an Eczema Priority Setting Partnership exercise in association with James Lind Alliance and other stakeholders.
- Consolidate our role as a 'hub' for patient and public involvement in eczema research, promoting research engagement opportunities and disseminating research findings.

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

Advocacy and Improving Eczema Care

- Increase public awareness and understanding of the challenges of living with eczema, highlighting the impact on people's physical and mental health and quality of life.
- Lead the annual national flagship awareness event, National Eczema Week in September.
- Raise awareness of the Society's successful campaign for clearer strength labelling of topical steroids.
- Continue to support initiatives to promote greater understanding, diagnosis and treatment of topical steroid withdrawal.
- Contribute patient perspectives to clinical guideline development and the assessment of new treatments and policy consultations, working with regulatory bodies including the MHRA, NICE and the SMC.

Financial Results

The Society planned for a modest budget surplus in 2024, following the annual £19,698 operating surplus achieved in 2023.

Income for the year was £529,182, with expenditure at £512,724, generating an annual surplus of £6,922. At 31 December 2024, the Society had reserves of £677,689 (2023: £670,767).

Reserves Policy

The trustees aim to maintain adequate reserves to permit the ongoing operations of the charity. In arriving at their assessment of a suitable limit, trustees have considered the predictability of the Society's income and the nature of its expenditure, together with the degree to which these are committed. Legacies form an important part of the Society's income, and whilst legacies can often be substantial relative to overall income, they are unpredictable, and historical trends show there can be periods of years where this source of income is much lower than the long-term average. Expenditure, on the other hand, is more consistent and predictable.

Trustees last reviewed the Reserves Policy in 2022, and considered that holding unrestricted reserves equal to approximately six months unrestricted charitable expenditure would be sufficient to close or merge the charity, should this ever be necessary. Given the known volatility of legacy income, trustees subsequently determined that a reserves target of 12 months' future overheads expenditure would be more appropriate. However, additional spend on research in 2025 meant that this policy was not met at the end of 2024 and the trustees will be conducting a further review of reserves policy ahead of the next accounts.

To make unrestricted reserves more transparent, funds that are not readily available to spend are held in reserves designated for specific purposes. A key aim of the Society is to promote research into the causes and treatment of eczema. This being so, the trustees have designated a proportion of reserves to fund future research activity, in addition to any funds that donors have specifically restricted for this purpose. Funds that are not readily available to spend, notably those represented by fixed assets, are held in a reserve designated for this purpose. The pension reserve shows future deficit payments owed in relation to an historical defined benefit pension scheme (see note 20).

The balance held in unrestricted funds at 31 December 2024 is £659,989 (2023: £664,016). Unrestricted funds include funds tied up in tangible assets of £4,372 (2023: £12,903), the pension reserve of (£9,896) (2023: (£4,567)), and designated Research funds of £110,000 (2023: £110,000). The remaining general funds of £555,513 (2023: £545,680) fall below the charity's reserves policy target of 12 months future overheads expenditure, budgeted at £752,600 for the 2025 financial year.

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

Risk Management

The trustees have taken steps to identify and address major risks facing the Society, including maintaining a risk register. The principal uncertainty in respect to the Society's future is the ability to maintain sufficient income to deliver the charity's operations, and ensure the Society has adequate resources to comply with regulatory changes affecting the voluntary sector. Greater focus and investment are being directed to fundraising activities, to ensure the Society generates sufficient income each year to fund planned activities. This includes building sustainable sources of non-legacy income.

The principal risk of financial sustainability for the charity is closely monitored by the trustees on a regular basis, including reviewing management accounts at quarterly Board meetings. Attention also continues to focus on non-financial risks including reputation, health and safety, security, confidentiality and data protection, which are supported by appropriate policies and procedures as well as management updates as needed.

The Trustees and Organisation

The Society is a charitable company. Although called trustees, we are the directors of the company for the purposes of company law. The trustees who served during the year and up to the date of this report are given on page 1.

The Society's governance processes are set out in its Articles of Association. The Board of Trustees administers the Society, which meets routinely four times a year and additionally as circumstances demand. A chief executive is appointed by the trustees to manage the day-to-day operations of the Society within a framework agreed by the B There must be a minimum of three trustees but there is no maximum number, and trustees must be elected by the members of the Society at its Annual General Meeting (AGM). Trustees may be co-opted onto the Board during the year and must then stand for election by the members at the next AGM. At least a third of trustees are required to retire from office each year but may, if they wish, offer themselves for re-election at the next AGM. Trustees are recruited through the Society's membership, local support groups, other eczema community networks and open advertising. In seeking trustees, the Society has regard of the need to ensure that the Trustee Board has an appropriate range of professional skills and experience, reflects our commitment to diversity, and are trustees are drawn from different areas of the UK.

Although not constitutionally binding, the Society wishes to work towards aligning with the Charity Governance Code, which recommends trustees serve fixed terms in office. The guidance recommends trustees serve an initial three-year term, with the possibility of being re-elected by members for a further three-year period. Trustees in particular roles (e.g. Chair, Treasurer) could serve a longer nine-year period, subject to formal review. One current trustee has served longer than nine years and provides specific professional skills to the Board. As yet, it has not been possible to find a replacement with comparable expertise.

New trustees are provided with an introduction pack, which includes the Society's governing documents, copies of the past year's accounts, and a briefing on their duties and responsibilities and of the Society's governance processes. Prior to joining the Board, new trustees will usually attend at least one Board meeting in an observer capacity, which gives them the opportunity to meet the trustees and chief executive.

Trustees receive no remuneration and no trustee has a beneficial interest in any of the group companies.

The Society has a Medical Advisory Board (MAB), comprised of healthcare professionals who act in an advisory and ambassadorial capacity for the charity. Members volunteer their time and are all experienced healthcare professionals who work in the field of dermatology, and who have a particular professional interest in eczema management and research. The MAB is chaired by National Eczema Society trustee, Professor Celia Moss.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

The trustees set the remuneration of the chief executive and approve the remuneration of other Society staff. Remuneration levels are based on research of similar roles in the sector and benchmark salary data.

The Trustees Report has been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

Approved by order of the members of the board of Trustees and signed on their behalf by:



Stephen Pugh
Chair
September 23, 2025
Date.....

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEMBER 2024


The Trustees (who are also the directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial . Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and the Charity and of their incoming resources and application of resources, including their income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Group and the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Group and the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the Board of Trustees and signed on its behalf by:


Stephen Pugh
Chair

Date: September 23, 2025

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024

Independent Examiner's Report to the Trustees of National Eczema Society ('the Group')

I report to the Charity Trustees on my examination of the consolidated accounts of the Group, set out on pages 14 to 45, comprising the National Eczema Society ('the parent Charity') and its subsidiary undertakings for the year ended 31 December 2024.

Responsibilities and Basis of Report

As the Trustees of the parent Charity (and its directors for the purposes of company law) you are responsible for the preparation of the consolidated accounts of the Group in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the consolidated accounts are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Group's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Since the Group's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe in any material respect:

1. accounting records were not kept in respect of the parent Charity and its subsidiaries as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

INDEPENDENT EXAMINER'S REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed:



Dated: 23 September 2025

Rachel Doyle ACA DChA

MHA
Chartered Accountants
MHA House
Charter Court
Swansea Enterprise Park
Swansea
SA7 9FS

MHA is the trading name of MHA Audit Services LLP, a limited liability partnership in England and Wales (registered number OC455542).

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2024

	Note	Unrestricted funds 2024 £	Restricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Income from:					
Donations and legacies	4	512,330	-	512,330	481,158
Other trading activities:	5				
Income from fundraising		91	-	91	5,732
Income from trading activities		2,462	-	2,462	2,965
Investments	6	14,299	-	14,299	7,397
Total income		529,182	-	529,182	497,252
Expenditure on:					
Raising funds		101,913	-	101,913	71,317
Charitable activities	8	410,811	-	410,811	406,245
Total expenditure		512,724	-	512,724	477,562
Net income		16,458	-	16,458	19,690
Transfers between funds	21	(10,949)	10,949	-	-
Net movement in funds before other recognised gains		5,509	10,949	16,458	19,690
Other recognised gains/(losses):					
Gains/(losses) on pension scheme		(9,536)	-	(9,536)	8
Net movement in funds		(4,027)	10,949	6,922	19,698
Reconciliation of funds:					
Total funds brought forward		664,016	6,751	670,767	651,069
Net movement in funds		(4,027)	10,949	6,922	19,698
Total funds carried forward		659,989	17,700	677,689	670,767

The Consolidated Statement of Financial Activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The notes on pages 21 to 45 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CONSOLIDATED BALANCE SHEET
AS AT 31 DECEMBER 2024

	Note	2024 £	2024 £	2023 £	2023 £
Fixed assets					
Intangible assets	14		2,255		1,462
Tangible assets	15		2,117		10,733
			4,372		12,195
Current assets					
Debtors: Amounts falling due within one year	17	116,944		88,906	
Investments	18	253,616		-	
Cash at bank and in hand		428,458		728,799	
		799,018		817,705	
Current liabilities					
Creditors: Amounts falling due within one year	19	(118,750)		(158,773)	
Net current assets			680,268		658,932
Total assets less current liabilities			684,640		671,127
Creditors: Amounts falling due after more than one year	20		(6,951)		(360)
Total net assets			677,689		670,767
Group funds					
Restricted funds	21		17,700		6,751
Unrestricted funds	21		659,989		664,016
Total funds			677,689		670,767

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CONSOLIDATED BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:



.....
Stephen Pugh
Chair
Date: September 23, 2025

The notes on pages 21 to 45 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CHARITY BALANCE SHEET
AS AT 31 DECEMBER 2024

	Note	2024 £	2024 £	2023 £	2023 £
Fixed assets					
Intangible assets	14		2,255		1,462
Tangible assets	15		2,117		10,733
Investments	16		100		100
			4,472		12,295
Current assets					
Debtors: Amounts falling due within one year	17	116,944		154,841	
Investments	18	253,616		-	
Cash at bank and in hand		336,093		581,497	
		706,653		736,338	
Current liabilities					
Creditors: Amounts falling due within one year	19	(124,480)		(115,791)	
Net current assets			582,173		620,547
Total assets less current liabilities			586,645		632,842
Creditors: Amounts falling due after more than one year	20		(6,951)		(360)
Total net assets			579,694		632,482
Charity funds					
Restricted funds	21		-		6,751
Unrestricted funds	21		579,694		625,731
Total funds			579,694		632,482

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CHARITY BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024

The Charity's net movement in funds for the year was £(52,788) (2023 - £(48,111)).

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:



.....
Stephen Pugh
Chair
Date: September 23, 2025

The notes on pages 21 to 45 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2024

	Note	2024 £	2023 £
Cash flows from operating activities			
Net cash used in operating activities	22	(308,540)	38,315
Cash flows from investing activities			
Investment income		14,299	7,397
Purchase of intangible assets		(2,000)	(2,021)
Purchase of tangible fixed assets		(4,100)	(2,000)
Net cash provided by investing activities		8,199	3,376
Change in cash and cash equivalents in the year		(300,341)	41,691
Cash and cash equivalents at the beginning of the year		728,799	687,108
Cash and cash equivalents at the end of the year	23	428,458	728,799

The notes on pages 21 to 45 form part of these financial statements

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1. General information

National Eczema Society is a charitable company limited by guarantee and is registered with the Registrar of Companies (Company Registered Number: 02685083), the Charity Commission in England and Wales (Charity Registered Number: 1009671).

In the event of the Charity being wound up, the liability in respect of the guarantee is limited to £1 per Member of the Charity.

The address of the registered office is given in the Charity information on page 1 of these financial statements. The nature of the Charity's operations and principal activities are detailed in the Trustees' Report.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

National Eczema Society meets the definition of a public benefit entity under FRS 102.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The Consolidated Statement of Financial Activities (SOFA) and Consolidated Balance Sheet consolidate the financial statements of the Charity and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

The financial statements are prepared in sterling which is the functional and presentational currency of the Group and are rounded to the nearest pound.

2.2 Going concern

The Trustees have assessed the use of going concern and have considered possible events or conditions that might cast significant doubt on the ability of the Group to continue as a going concern. The Trustees have made this assessment for a period of at least one year from the date of the approval of these financial statements. The Trustees have concluded that there is a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future, and that no material uncertainties exist. The Group therefore continues to adopt the going concern basis in preparing these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. Accounting policies (continued)

2.3 Income

All income is recognised once the Group has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

For donations and gift aid to be recognised the Group will have been notified of the amounts and the settlement date in writing. If there are conditions attached to the donation and this requires a level of performance before entitlement can be obtained then income is deferred until those conditions are fully met or the fulfilment of those conditions is within the control of the Group and it is probable that they will be fulfilled.

The recognition of income from legacies is dependent on establishing entitlement, the probability of receipt and the ability to estimate with sufficient accuracy the amount receivable. Evidence of entitlement to a legacy exists when the Group has sufficient evidence that a gift has been left to them (through knowledge of the existence of a valid will and the death of the benefactor) and the executor is satisfied that the property in question will not be required to satisfy claims in the estate. Receipt of a legacy must be recognised when it is probable that it will be received and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the Group, can be reliably measured.

Subscription income is received in full and recognised evenly over the course of the subscription. The amount recognised in the Consolidated Statement of Financial Activities relates to the financial period in question.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the Group. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

Corporate membership income is received in full and recognised evenly over the course of the membership. The amount recognised in the Consolidated Statement of Financial Activities relates to the financial period in question.

2.4 Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the categories. Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Group's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. Accounting policies (continued)

2.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Group; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.6 Taxation

The Charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

2.7 Intangible assets and amortisation

Intangible assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Amortisation is provided on intangible assets at rates calculated to write off the cost of each asset on a straight-line basis over 3 years.

Assets under construction are not amortised until ready for use.

2.8 Tangible fixed assets and depreciation

Tangible fixed assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

At each reporting date the Group assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined to be the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. Accounting policies (continued)

2.8 Tangible fixed assets and depreciation (continued)

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following bases:

Leasehold improvements	- over 10 years
Furniture and fittings	- over 10 years
Office equipment	- over 10 years
Computer equipment	- over 3 years

2.9 Investments

The investment in the subsidiary company is valued at cost less provision for impairment.

2.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Group anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Consolidated Statement of Financial Activities as a finance cost.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. Accounting policies (continued)

2.13 Financial instruments

The Group only holds basic Financial Instruments. The financial assets and financial liabilities of the Group are as follows:

Debtors – other debtors are basic financial instruments and are debt instruments measured at amortised cost as detailed in Note 17.

Cash at bank – is classified as a basic financial instrument and is measured at face value.

Liabilities – accruals are classified as financial instruments, and are measured at amortised cost as detailed in Notes 19 and 20.

2.14 Operating leases

Rentals paid under operating leases are charged to the Consolidated Statement of Financial Activities on a straight line basis over the lease term.

2.15 Pensions

Through its past participation, the Group has a liability to a pension scheme called the Series 3 Growth Plan, which closed in 2013. Since then, the Group has participated in a defined contribution pension scheme for employees, operated by workplace pension provider TPT.

The Group is part of the Series 3 Growth Plan which is a multi-employer pension Scheme which closed in 2013. The Scheme administrators have confirmed that it is not possible to separately identify the assets and liabilities of participating employers on a consistent and reasonable basis. The assets of the Scheme are co-mingled for investment purposes and benefits are paid from total Scheme assets. A deficit reduction plan has been agreed.

The Group accounts for its participation in this Plan as a defined contribution plan, as there is insufficient information available to account for this as a defined benefit plan, as the share of its assets and liabilities cannot be identified.

To avoid crystallizing an immediate payment of the apparent under-funding in the Series 3 Scheme, the Group is participating in the Series 3 Recovery Plan and the liability is included in Notes 19 and 20. The Group recognises its liability to make payments to fund the deficit relating to past service under an agreement to make those payments. It recognises the full liability for the present value of contributions payable that results from the agreement for funding the multi employer plan.

The Group also participates in a defined contribution pension scheme for its employees. The Group pays fixed contributions into a separate scheme. Once the defined contribution payments have been made, the Group has no further payment obligations in respect of this scheme. The contributions are recognised as an expense in the Consolidated Statement of Financial Activities as they fall due.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. Accounting policies (continued)

2.16 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Group for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Critical accounting estimates and areas of judgement

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The Group makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are listed below.

- Allocation of support costs
- Legacy income recognition
- Depreciation rates for tangible fixed assets
- Useful economic lives of assets
- The discount rate used in valuing the year-end Pension Scheme deficit.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

4. Income from donations and legacies

	Unrestricted funds 2024 £	Total funds 2024 £
Donations and similar income	175,519	175,519
Legacies	189,454	189,454
Subscriptions	126,734	126,734
Gift aid	20,623	20,623
Total 2024	512,330	512,330

	Unrestricted funds 2023 £	Total funds 2023 £
Donations and similar income	205,431	205,431
Legacies	110,610	110,610
Subscriptions	141,813	141,813
Gift aid	23,304	23,304
Total 2023	481,158	481,158

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

5. Income from other trading activities

Income from fundraising events

	Unrestricted funds 2024 £	Total funds 2024 £
Other activities	91	91

	Unrestricted funds 2023 £	Total funds 2023 £
Other corporate income	2,896	2,896
Other activities	2,836	2,836
Total 2023	5,732	5,732

Income from non charitable trading activities

	Unrestricted funds 2024 £	Total funds 2024 £
Trading subsidiary	2,462	2,462

	Unrestricted funds 2023 £	Total funds 2023 £
Trading subsidiary	2,965	2,965

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

6. Income from investments

	Unrestricted funds 2024 £	Total funds 2024 £
Bank interest receivable	14,299	14,299
	Unrestricted funds 2023 £	Total funds 2023 £
Bank interest receivable	7,397	7,397

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

7. Expenditure on raising funds

	2024 £	2023 £
Fundraising costs		
Direct costs	78,339	65,707
Support costs	23,572	5,604
	101,911	71,311

Analysis of support costs - fundraising costs

	2024 £	2023 £
Staff costs	6,368	1,912
Depreciation	1,212	382
Premises costs	2,451	728
Carriage and postage	264	116
HCP services and fees	149	33
Professional fees	1,377	349
Bought-in services	129	41
Website, database and computing	3,794	712
Other costs	6,757	835
Governance costs	1,071	496
	23,572	5,604

	2024 £	2023 £
Trading costs		
Trading subsidiary - Direct costs	2	6

In both the current and previous financial years all Expenditure on raising funds was from Unrestricted funds.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

8. Analysis of expenditure on charitable activities - by fund

	Unrestricted funds 2024 £	Total 2024 £
Communications, awareness and campaigns	88,371	88,371
Health Information and Advice	219,290	219,290
Research	103,150	103,150
Total 2024	410,811	410,811
	Unrestricted funds 2023 £	Total 2023 £
Helpline	110,547	110,547
Membership services	181,415	181,415
Information services	114,283	114,283
Total 2023	406,245	406,245

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

9. Analysis of expenditure on charitable activities - by type

	Activities undertaken directly 2024 £	Support costs 2024 £	Total funds 2024 £
Communications, awareness and campaigns	12,523	75,848	88,371
Health Information and Advice	101,432	117,858	219,290
Research	79,577	23,573	103,150
Total 2024	193,532	217,279	410,811

	Activities undertaken directly 2023 £	Support costs 2023 £	Total funds 2023 £
Helpline	60,804	49,743	110,547
Membership services	102,860	78,555	181,415
Information services	73,335	40,948	114,283
Total 2023	236,999	169,246	406,245

During the year the charity restructured its activities and therefore the prior year is not directly comparable to the current year. If the current year was allocated on the same basis as previous years the total expenditure for each activity would be as follows:

Raising Funds £86,710

Helpline £108,713

Membership services £201,896

Information services £106,405

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

9. Analysis of expenditure on charitable activities - by type (continued)

Analysis of support costs

	Total funds 2024 £	Total funds 2023 £
Staff costs	57,314	55,947
Depreciation	10,910	11,165
Premises costs	22,064	21,302
Carriage and postage	2,373	3,399
Professional fees	12,390	13,130
Bought-in services	1,161	1,205
Website, database and computing	34,149	20,833
Insurance	231	1,750
Other costs	65,711	27,930
Governance costs	9,636	11,619
HCP services and fees	1,340	966
	217,279	169,246

10. Governance costs

	2024 £	2023 £
Independent Examiner's remuneration	2,535	2,000
Staff training	-	2,065
Insurance	7,626	5,789
Recruitment	-	-
Room hire & Conference expenses	202	1,498
Trustees expenses	-	-
Travel, hotels & subsistence	344	639
General office expenses	-	26
	10,707	12,017

Total Governance costs above comprise £1,071 (2023 - £398) of Expenditure on raising funds and £9,636 (2023 - £11,619) of Expenditure on charitable activities.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

11. Auditors' and Independent examiner's remuneration

	2024 £	2023 £
Independent Examiner's remuneration - Examination of the financial statements	5,520	5,250

12. Staff costs

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Wages and salaries	238,434	212,525	238,434	212,525
Social security costs	23,212	19,710	23,212	19,710
Pension costs	7,849	10,327	7,849	10,327
	269,495	242,562	269,495	242,562

Included in Wages and salaries above are redundancy costs of £29,812 (2023: £NIL). Of this amount, £29,812 (2023: £NIL) relates to statutory redundancy.

The average number of persons employed by the Charity during the year was as follows:

	Group 2024 No.	Group 2023 No.
Direct charitable activities	3	3
Fundraising and communication	1	1
Support and governance	1	1
	5	5

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	Group 2024 No.	Group 2023 No.
In the band £60,001 - £70,000	-	1
In the band £70,001 - £80,000	1	-

The total amount of employee benefits, including employers national insurance and pension contributions, received by Key Management Personnel is £102,576 (2023 - £138,823). The Charity considers its Key Management Personnel comprise the Trustees and the Chief Executive Officer and deputy CEO.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

13. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2023 - £NIL).

During the year ended 31 December 2024, expenses totalling £147 were reimbursed or paid directly to 1 trustee (2023 - £499 - 2 Trustees) in relation to travel and conference costs.

14. Intangible assets

Group and Charity

	Website £
Cost	
At 1 January 2024	23,009
Disposals	(20,988)
Revaluations	2,000
At 31 December 2024	4,021
Amortisation	
At 1 January 2024	21,547
Charge for the year	1,210
On disposals	(20,991)
At 31 December 2024	1,766
Net book value	
At 31 December 2024	2,255
At 31 December 2023	1,462

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

15. Tangible fixed assets

Group and Charity

	Leasehold improvements £	Furniture and fixtures £	Office equipment £	Computer equipment £	Total £
Cost or valuation					
At 1 January 2024	41,470	2,493	3,873	26,189	74,025
Additions	1,330	-	-	2,770	4,100
Disposals	-	-	(177)	(22,044)	(22,221)
Transfers between classes	-	-	-	(2,000)	(2,000)
At 31 December 2024	42,800	2,493	3,696	4,915	53,904
Depreciation					
At 1 January 2024	34,230	2,178	3,063	23,821	63,292
Charge for the year	8,570	315	540	1,288	10,713
On disposals	-	-	(177)	(22,041)	(22,218)
At 31 December 2024	42,800	2,493	3,426	3,068	51,787
Net book value					
At 31 December 2024	-	-	270	1,847	2,117
At 31 December 2023	7,240	315	810	2,368	10,733

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

16. Fixed asset investments

Charity	Investment in subsidiary company £
Cost or valuation	
At 1 January 2024	100
At 31 December 2024	100

Principal subsidiaries

The following was a subsidiary undertaking of the Charity:

Name	Company number	Registered office or principal place of business	Holding	Included in consolidation
Eczema Trading Limited	06895048	82 Tanner Street, London, SE1 3GN	100%	Yes

The financial results of the subsidiary for the year were:

Name	Income £	Expenditure £	Profit for the year £	Net assets £
Eczema Trading Limited	69,712	(5,002)	64,710	103,095

The results of Eczema Trading Limited are included in these consolidated accounts. Eczema Trading Limited did not meet the audit threshold and therefore did not require an audit for the year ended 31 December 2024. The reported surplus relates to intercompany management charges and minimal advertising and corporate membership revenue.

For the year ended 31 December 2024, Corporate memberships, the advertising revenue from our membership magazine, together with limited income from company supporters, is accounted for in Eczema Trading Limited.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

17. Debtors

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Due within one year				
Trade debtors	-	20,762	-	2,762
Amounts owed by group undertakings	-	-	-	83,935
Other debtors	94,075	50,622	94,075	50,622
Prepayments and accrued income	22,869	17,522	22,869	17,522
	116,944	88,906	116,944	154,841

18. Current asset investments

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
95 day savings accounts	253,616	-	253,616	-

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

19. Creditors: Amounts falling due within one year

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Trade creditors	2,881	5,127	2,881	5,127
Amounts owed to group undertakings	-	-	41,462	-
Other taxation and social security	12,326	15,401	12,326	15,401
Other creditors	3,998	4,395	3,998	4,395
Accruals and deferred income	99,545	133,850	63,813	90,868
	118,750	158,773	124,480	115,791
	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Deferred income				
Deferred income at 1 January	115,512	78,080	72,530	50,447
Resources deferred during the year	97,525	164,308	15,000	77,409
Amounts released from previous periods	(133,616)	(126,876)	(45,916)	(55,326)
Deferred income at 31 December	79,421	115,512	41,614	72,530

Deferred income consists of membership income relating to future periods.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

20. Creditors: Amounts falling due after more than one year

	Group 2024	Group 2023	Charity 2024	Charity 2023
	£	£	£	£
Pension Scheme deficit	6,951	360	6,951	360

Through its past participation, the Group has a liability to a pension scheme called the Series 3 Growth Plan, which closed in 2013. Since then, the Group has participated in a defined contribution pension scheme for employees, operated by workplace pension provider TPT.

The Charity is participating in a recovery plan to eliminate its Series 3 scheme deficit over a ten year period. The Pensions Trust, the scheme administrator, has however advised that the amount of employer debt on the alternative of withdrawal from the Series 3 scheme has been estimated by actuaries to have been £200,161 as at 31 December 2016. As the Charity intends to continue participating in the recovery plan, no provision has been made for this potential withdrawal debt however, the Society accounted for the present value of all remaining contributions under the recovery plan in the 2017 accounts at their present value of £120,000, as advised by the scheme administrator. This liability has been adjusted annually to unwind the relevant discount applied.

In order to meet their share of the shortfall, the Charity has been asked to pay additional contributions to the scheme. A full actuarial valuation was carried out by the actuaries during the year and the funding shortfall calculated at that date gave rise to a remeasurement reduction of £9,896 in the deficit as at 31 December 2024. The deficit of the scheme is £9,896, (2023 - £4,556) at 31 December 2024. The payment by the Charity in the year was £4,324 (2023 - £4,324) with an interest payment of £129 (2023 - £311) and a revaluation gain of £Nil (2023 - £8).

In addition, the Charity elected to switch, with effect from 1 October 2013, from Series 3 to Series 4, a defined contribution scheme. The pension cost in the accounts represents amounts payable by the charity as ordinary employer contributions to the Series 4 defined contribution fund.

During the year employer contributions of £7,849 (2023 - £10,327), interest of £42 (2023 - £311), actuarial (gains)/losses of £Nil (2023 - £8) and remeasurements for amendments to the contribution schedule of £9,525 (2023 - £Nil) have been charged to the Consolidated Statement of Financial Activities, along with scheme costs of £5,091 (2023: £3,625). There were no accrued contributions at 31 December 2024 (2023 - £NIL) but there is a liability of £9,896 (2023 - £4,566) for future contributions under the Series 3 Recovery Plan. Of this £2,945 (2023 - £4,206) is reported in Creditors: Amounts falling due within one year as part of Other creditors and £6,951 (2023 - £360) is reported in Creditors: Amounts falling due after more than one year.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

21. Statement of funds

Statement of funds - current year

	Balance at 1 January 2024 £	Income £	Expenditure £	Transfers in/(out) £	Gains/ (Losses) £	Balance at 31 December 2024 £
Unrestricted funds						
Designated funds						
Fixed asset fund	12,903	-	(10,910)	2,379	-	4,372
Pension reserve	(4,567)	-	(5,132)	9,339	(9,536)	(9,896)
Research fund	110,000	-	-	-	-	110,000
	<u>118,336</u>	<u>-</u>	<u>(16,042)</u>	<u>11,718</u>	<u>(9,536)</u>	<u>104,476</u>
General funds						
General funds	<u>545,680</u>	<u>529,182</u>	<u>(496,682)</u>	<u>(22,667)</u>	<u>-</u>	<u>555,513</u>
Total Unrestricted funds	<u>664,016</u>	<u>529,182</u>	<u>(512,724)</u>	<u>(10,949)</u>	<u>(9,536)</u>	<u>659,989</u>
Restricted funds						
Research	<u>6,751</u>	<u>-</u>	<u>-</u>	<u>10,949</u>	<u>-</u>	<u>17,700</u>
Total of funds	<u><u>670,767</u></u>	<u><u>529,182</u></u>	<u><u>(512,724)</u></u>	<u><u>-</u></u>	<u><u>(9,536)</u></u>	<u><u>677,689</u></u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

21. Statement of funds (continued)

Statement of funds - prior year

	Balance at 1 January 2023 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 December 2023 £
Unrestricted funds						
Designated funds						
Fixed asset fund	19,721	-	(10,839)	4,021	-	12,903
Pension reserve	(8,587)	-	(5,579)	9,591	8	(4,567)
Research fund	110,000	-	-	-	-	110,000
	<u>121,134</u>	<u>-</u>	<u>(16,418)</u>	<u>13,612</u>	<u>8</u>	<u>118,336</u>
General funds						
General funds	<u>523,185</u>	<u>497,252</u>	<u>(461,145)</u>	<u>(13,612)</u>	<u>-</u>	<u>545,680</u>
Total Unrestricted funds	<u>644,319</u>	<u>497,252</u>	<u>(477,563)</u>	<u>-</u>	<u>8</u>	<u>664,016</u>
Restricted funds						
Research	<u>6,751</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>6,751</u>
Total of funds	<u><u>651,070</u></u>	<u><u>497,252</u></u>	<u><u>(477,563)</u></u>	<u><u>-</u></u>	<u><u>8</u></u>	<u><u>670,767</u></u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

21. Statement of funds (continued)

Designated funds

The Pension reserve has been established to show the future pension deficit payments in regards to a defined benefit pension scheme. This pension scheme is being treated as a defined contribution pension scheme as a reliable estimate cannot be made of the liability at the year end. The transfer of £9,339, was made to separate the deficit payments due as at 31 December 2024 from the Unrestricted general fund. Actuarial gains / (losses) are charged to this fund as they arise.

The Fixed asset fund has been established to reflect the funds tied up in Tangible and Intangible fixed assets and agrees back to the Net Book Value presented on the Consolidated Balance Sheet. Depreciation is charged to this fund as expenditure.

The Research fund has been established to designate funds for research into the causes and treatment of eczema, which is a key aim of the Society. The Society will provide grants to researchers on a periodic basis and it is necessary to designate sufficient reserves to fund the expected grant costs.

Unrestricted funds

General funds reflects funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds

The Research fund exists to provide resources for research into the causes of eczema, with the aim of developing more effective treatments or a cure.

22. Reconciliation of net movement in funds to net cash flow from operating activities

	Group 2024 £	Group 2023 £
Net income for the period (as per Statement of Financial Activities)	16,458	19,690
Adjustments for:		
Depreciation charges	10,713	9,152
Amortisation charges	1,210	2,395
Dividends, interests and rents from investments	(14,299)	(7,397)
Loss on the sale of fixed assets	2,000	-
Increase in debtors	(281,654)	(53,516)
(Decrease)/increase in creditors	(33,432)	60,041
Actuarial Gains/ (loss) on pension	(9,536)	-
Net cash provided by/(used in) operating activities	(308,540)	30,365

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

23. Analysis of cash and cash equivalents

	Group 2024 £	Group 2023 £
Cash in hand	428,458	728,799
Total cash and cash equivalents	428,458	728,799

24. Analysis of changes in net debt

	At 1 January 2024 £	Cash flows £	At 31 December 2024 £
Cash at bank and in hand	728,799	(300,341)	428,458
95 day savings accounts	-	253,616	253,616
	728,799	(46,725)	682,074

25. Operating lease commitments

At 31 December 2024 the Group and the Charity had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Not later than 1 year	30,600	21,000	30,600	21,000
Later than 1 year and not later than 5 years	-	4,333	-	4,333
	30,600	25,333	30,600	25,333

The following lease payments have been recognised as an expense in the Statement of Financial Activities:

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Operating lease rentals	21,000	21,000	21,000	21,000

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

26. Related party transactions

In the year ended 31 December 2024, unrestricted donations of £120 (2023 - £120) were made by the Trustees of the Charity.

27. Post balance sheet events

The charity has received a legacy from the Morton Estate. There are a number of assets that are in the process of being sold and therefore the expected legacy could not be accurately valued at the year end.

The charity also received a legacy from Enid Mary Shores Estate. The amount received could not be quantified at the year end.